Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net

ARTIVION, INC.

Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.
Adjusted EBITDA $22.1M (+26% YoY); non-GAAP net income $4.2M ($0.08 diluted EPS) vs $2.5M ($0.06) in prior year.
Full-year 2026 revenue guidance lowered to $480-496M (prev $486-504M); adjusted EBITDA guidance lowered to $100-107M (prev $105-110M).
Exercised option to acquire Endospan; base price $175M, net ~$135M after offsetting loans; contingent consideration up to $200M; closing expected Q2 2026.
FDA approved NEXUS Aortic Arch System on April 2, 2026, triggering option exercise; commercial launch planned Jan 1, 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARTIVION, INC. reported first quarter ended March 31, 2026 results: revenue $116.3 million, net income $1.4 million, EPS $0.03 per fully diluted share. Guidance lowered.

Period: first quarter ended March 31, 2026
Revenue: $116.3 million
Net income: $1.4 million
EPS: $0.03 per fully diluted share
Guidance: lowered
Result: reported results

Exact text from the filing

Total revenues for the first quarter of 2026 were $116.3 million, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis, both compared to the first quarter of 2025. Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted common share, compared to net loss of $(0.5) million, or $(0.01) per fully diluted common share for the first quarter of 2025.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARTIVION, INC. entered into Securities Purchase Option Agreement with Endospan Ltd., the securityholders of Endospan listed on Schedule 1, and Shareholder Representative Services LLC valued at base purchase price of $175.0 million (effective 2019-09-11).

Action: entry
Agreement: equity purchase
Counterparty: Endospan Ltd., the securityholders of Endospan listed on Schedule 1, and Shareholder Representative Services LLC
Value: base purchase price of $175.0 million
Effective: 2019-09-11

Exact text from the filing

on September 11, 2019, Artivion, Endospan, the securityholders of Endospan listed on Schedule 1 thereto (together with any additional securityholder that becomes a party by joinder, the “Securityholders”), and Shareholder Representative Services LLC, as the Securityholder representative, entered into a Securities Purchase Option Agreement

View on SEC.gov

Browse all earnings releases →

ARTIVION, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-032097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.